ducovest

IBDS:NYE-iShares iBonds Dec 2027 Term Corporate ETF (USD)

ETF | Target Maturity |

Last Closing

USD 24.14

Change

+0.04 (+0.17)%

Market Cap

USD 2.61B

Volume

0.43M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index. The index is composed of U.S. dollar-denominated, investment-grade corporate bonds maturing in 2027.

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Target Maturity

Symbol Name Price(Change) Market Cap
IBDR iShares iBonds Dec 2026 Term C..

+0.01 (+0.04%)

 USD 2.91B
IBDQ iShares iBonds Dec 2025 Term C..

N/A

 USD 2.85B
IBDT iShares iBonds Dec 2028 Term C..

+0.02 (+0.08%)

 USD 2.28B
IBDP iShares iBonds Dec 2024 Term C..

N/A

 N/A

ETFs Containing IBDS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Target Maturity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.88% 80% B- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.88% 80% B- 43% F
Trailing 12 Months  
Capital Gain 5.05% 80% B- 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.05% 80% B- 37% F
Trailing 5 Years  
Capital Gain -7.15% 80% B- 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.15% 80% B- 46% F
Average Annual (5 Year Horizon)  
Capital Gain -2.27% 80% B- 24% F
Dividend Return 0.16% 80% B- 23% F
Total Return 2.44% 80% B- 54% F
Risk Return Profile  
Volatility (Standard Deviation) 6.17% 80% B- 89% A-
Risk Adjusted Return 2.64% 80% B- 24% F
Market Capitalization 2.61B 50% F 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.